

Special Issue

Multidrug Resistance in Cancer: Genetic and Protein Biomarkers and Tools to Overcome MDR in Patients and Experimental Models

Message from the Guest Editor

Tumor multidrug resistance (MDR) is one of the most important impediments in the treatment of cancer. Finding MDR determinants and tools to overcome this phenomenon is necessary to improve the treatment of resistant tumors. At present, many studies using standardized genomic and proteomic profiling approaches have led to the discovery of molecular and protein biomarkers of therapeutic response and MDR in solid tumor patients. In addition to identifying the MDR profile, discovery of new therapeutic targets, MDR-reversal agents and drugs that are effective in resistant tumor cells present a promising approach for the treatment of resistant tumors. This Special Issue of *Biomedicines* focuses on recent original findings, characterization, translation, and clinical application of cancer genetic or proteomic biomarkers of resistance and therapeutic outcomes in solid tumor patients and experimental models. In the frame of MDR research, this issue also focuses on identification and characterization of potential and effective tools to overcome the phenomenon of MDR in solid tumors.

Guest Editor

Dr. Radka Vaclavikova

1. Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague 10, Czech Republic
2. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic

Deadline for manuscript submissions

closed (31 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/81644

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).